BL-M02D1 vs Sacituzumab Tirumotecan

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Non-Small Cell Lung Cancer

Shared mechanism: TROP2 · full Non-Small Cell Lung Cancer pipeline

BL-M02D1

Developed by Sichuan Baili Pharmaceutical

Phase 1/2 in Non-Small Cell Lung Cancerantibody-drug conjugate
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Sacituzumab Tirumotecan

Marketed by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. and partners

Phase 3 in Non-Small Cell Lung Cancerantibody-drug conjugate
Partial signal

NCT05870319 · Phase 3 · active, not recruiting

This is a randomized, adequately sized (n=376) trial with an active comparator (standard chemotherapy) and a hard clinical endpoint (progression-free survival), and the result was strongly positive favoring the drug. However, the study was conducted open-label with no blinding, which limits confidence in a design that would otherwise support a top-tier grade despite the clear and statistically robust result.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Next expected readout: November 2026 · NCT06448312 (registry estimate)

Reported efficacy

Progression-free survival (PFS) (From baseline until disease progression, death, or other protocol defined reason,up to approximately 36 months): OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 (met)

Result source: NCT05870319

Results for Non-Small Cell Lung Cancer

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointBL-M02D1Sacituzumab Tirumotecan
PFS, median—Not reported—Trial running · NCT05870319
OS, median—Not reported—Trial running · NCT05870319
ORR—Not reported—Trial running · NCT05870319
Duration of response, median—Not reported—Trial running · NCT05870319

PFS, median

BL-M02D1
—Not reported
Sacituzumab Tirumotecan
—Trial running · NCT05870319

OS, median

BL-M02D1
—Not reported
Sacituzumab Tirumotecan
—Trial running · NCT05870319

ORR

BL-M02D1
—Not reported
Sacituzumab Tirumotecan
—Trial running · NCT05870319

Duration of response, median

BL-M02D1
—Not reported
Sacituzumab Tirumotecan
—Trial running · NCT05870319
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

BL-M02D1: no structured comparison results are available for Non-Small Cell Lung Cancer.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Sacituzumab Tirumotecan
OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001 NCT05870319 · Phase 3 · design grade: moderate · publication or press release

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: BL-M02D1's landscape · Sacituzumab Tirumotecan's landscape